Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals was formerly known as CANCER METABOLISM THERAPEUTICS And changed its name to Agios Pharmaceuticals In April 2008. The company is based in Cambridge, Massachusetts.

Dong Wha Pharm Co., Ltd. engages in the manufacture and sale of pharmaceuticals and medicinal chemicals. Its products include medicines for digestion, skin scars, general cold, gum treatment, high blood pressure, infection, gastrointestinal tract control, and others. The company was founded on September 25, 1897 and is headquartered in Seoul, South Korea.

Servier are driven by the belief in the excellence of their profession. Theirs is a research-based organization, fulfilling a basic need and dedicated to the future.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Translational Drug Development is a biotechnology company intended to develop translational oncology support to treat cancer. Their platform conducts clinical programs that predict unique contexts of sensitivity for new medicines which then provide accelerated patient benefits in clinical testing, enabling oncology researchers to examine and prepare proper cancer drugs.

sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health. sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs. These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products. Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.

Anterogen Co., Ltd. engages in the development and sale of stem cell therapy treatments. Its products include Cupistem and Remodullin injection, Queencell, and stem cell conditioned media. It also offers stem cell banking and analysis services. The company was founded on March 16, 2000 and is headquartered in Seoul, South Korea.

Formerly Known as Vasculox. Arch Oncology is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.

Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.

Cilag AG is an international operating company integrated in the Janssen Pharmaceutical Companies of Johnson & Johnson that provides its customers with highest quality active pharmaceutical ingredients and pharmaceutical products worldwide. To achieve this they comply with worldwide Quality, Health, Safety and Environmental standards. These standards are basically ensured by their more than 1000 well trained and developed, conscientious and highly motivated employees, who are their most valuable capital.

Nerviano Medical Sciences SRL provides pharmaceutical services. The company is headquartered in Nerviano, Italy.

Genomictree Inc. is a company based out of South Korea.

Part of Servier SAS, Servier Pharmaceuticals LLC is an American company located in Boston, MA, that operates as a pharmaceuticals company. It was founded in 1954. David K. Lee is currently the CEO of the firm.\nThe company says this about itself: Servier Pharmaceuticals LLC is a commercial-stage company with a passion for innovation and improving the lives of patients, their families and caregivers. As a privately held company, Servier has the unique freedom to devote all of its time and energy towards patients who require our treatments, care and innovation in areas of unmet medical need. As a leader in oncology, Servier is committed to finding solutions that will address today's challenges. The company's oncology portfolio includes innovative medicines designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of research and development dedicated to delivering significant advances in areas of high unmet need that may truly move the needle for our patients. Servier believes co-creation is fundamental to driving innovation and is actively building alliances, acquisitions, licensing deals and partnerships that bring solutions and accelerate access to therapies.

Rahan Meristem is an agro-biotechnology company with more than 30 years of experience in plant propagation and breeding. They produce millions of plants every year and export to more than 20 countries around the world. They are a privately owned company headquartered in Rosh Hanikra, Israel, with additional production facilities in Colombia, the Philippines and Ecuador, and a distribution center in Costa Rica.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients.

Good health and a happy life is something all people rightly aspire to. They believe everyone on the planet deserves access to quality health care. Finding affordable solutions to today's health care challenges demands cutting-edge science, highly talented and motivated people and above all the ability to innovate. Innovation and continuous improvement are the heartbeat of their company. Their mission is to make health care more affordable, increasing access to important medicines through the provision of high quality small molecule generics, and new biological and new chemical entities.

The Group's principal activity is to produce pharmaceuticals and chemicals. The operations are carried out through the following divisions: Pharmaceuticals; Bio chemical; Chemicals; Food and Other. Pharmaceuticals include ethical drugs, bulk pharmaceuticals and biological research. Bio chemicals deal with biochemical diagnostic reagents, animal health products, agrochemicals and fertilizers. Chemicals includes solvents, plasticizes and their raw materials, detergent raw materials and specialty chemicals. Food includes alcoholic beverages, alcohol, seasonings, confectionery, baking ingredients and processed foods. Others include wholesale, commodity distribution and installation of facilities.